A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Preliminary Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bryostatin 1 in Patients With Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2017
Price : $35 *
At a glance
- Drugs Bryostatin-1 (Primary)
- Indications Alzheimer's disease
- Focus Proof of concept; Therapeutic Use
- Sponsors Neurotrope BioScience
- 17 Mar 2015 Results published in a Neurotrope BioScience media release.
- 24 Feb 2015 Top-line results published in a Neurotrope BioScience media release.
- 24 Feb 2015 Status changed from recruiting to completed, as reported in a Neurotrope BioScience media release.